PUNE, India, Sept. 25, 2026 /PRNewswire/ -- The Global AI in Clinical Trials Market was valued at USD 2 Billion in 2025 and is projected to grow at a 15.5% CAGR from 2026 to 2034, reaching USD 7.32 Billion by 2034, according to Maximize Market Research.

Global AI in Clinical Trials Market

The Global AI in Clinical Trials Market Report 2026 provides a detailed assessment of market trends, clinical research activity, AI adoption, patient recruitment, data analysis, safety monitoring, drug discovery, personalized medicine, trial-phase applications, end-user demand, competitive developments, and market forecasts through 2034. The market is segmented by Trial Phase, Technology, Application, End-Users, and Region, covering Phase I, Phase II, and Phase III trials; machine learning, natural language processing, and deep learning; and applications including patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

The market is expanding as pharmaceutical and biotechnology companies increasingly use AI to improve the speed and efficiency of clinical research. AI tools are being applied to patient screening, cohort selection, trial design, large-scale data analysis, safety evaluation, and treatment optimization. By analyzing complex patient datasets, AI can help researchers identify suitable trial participants, detect patterns more quickly, and support more targeted clinical decision-making.

Growing use of machine learning, deep learning, AI-driven patient monitoring, real-world evidence, decentralized trials, and AI-enabled drug discovery is creating new opportunities across the clinical research ecosystem. Pharmaceutical companies, CROs, hospitals, and research institutes are adopting AI to streamline workflows, improve patient recruitment, strengthen data quality, and reduce delays in drug development. These developments are expected to support the AI in Clinical Trials Market as it grows from USD 2 Billion in 2025 to USD 7.32 Billion by 2034 at a CAGR of 15.5%.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/222597/

Global AI in Clinical Trials Market gains momentum as pharmaceutical companies, CROs, and research institutions turn to AI for faster patient recruitment, smarter data analysis, improved safety monitoring, personalized medicine, and more efficient drug development, says Maximize Market Research.

Global AI in Clinical Trials Market Size & Forecast

Global AI in Clinical Trials Market Trends & Insights

- North America leads the Global AI in Clinical Trials Market, supported by strong healthcare infrastructure, a mature pharmaceutical industry, significant investment in AI research, and increasing collaboration between pharmaceutical and technology companies. The United States remains the key regional market, while Europe is also seeing rapid adoption across the UK, Germany, and France.

- AI adoption is reshaping patient recruitment and clinical trial operations by helping researchers identify suitable participants, analyze large patient datasets, improve cohort selection, and support trial design. These capabilities are helping reduce delays and improve the efficiency of clinical research.

- Machine learning, natural language processing, and deep learning are becoming central technologies across the AI in Clinical Trials Market. Their use is expanding in patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine across Phase I, Phase II, and Phase III trials.

- Pharmaceutical and biotechnology companies remain major adopters of AI in clinical research, using the technology to support drug discovery, trial execution, data analysis, and post-market surveillance. CROs, hospitals, research institutes, and government agencies are also increasing adoption as AI becomes more embedded in the clinical research ecosystem.

- Decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery are emerging as important market trends. Growing use of AI in diagnostics, treatment optimization, patient stratification, and personalized medicine is expected to create new opportunities as the Global AI in Clinical Trials Market advances toward 2034.

Faster Patient Recruitment and Data Analysis Drive Market Growth

The AI in Clinical Trials Market is gaining momentum as pharmaceutical companies, biotechnology firms, CROs, and research organizations look for faster and more efficient ways to manage clinical studies. AI is increasingly being used for patient screening, cohort selection, trial design, data analysis, and recruitment, helping researchers identify suitable participants and process large volumes of clinical information more quickly. These capabilities are improving trial efficiency while supporting faster drug development and better use of research resources.

Data Privacy, Regulatory Compliance, and Data Quality Restrain Adoption

Despite its potential, AI adoption in clinical trials faces important barriers. Data privacy concerns, regulatory compliance, data quality issues, and the need for specialized AI expertise can slow implementation across clinical research organizations. Because clinical trials handle sensitive patient information and operate under strict regulatory requirements, companies must ensure that AI systems are reliable, transparent, and supported by high-quality data before they can be widely integrated into trial workflows.

Decentralized Trials and AI-Driven Drug Discovery Create New Opportunities

The growing use of decentralized clinical trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery is opening new opportunities across the market. Machine learning, deep learning, and natural language processing are being applied to patient recruitment, safety monitoring, personalized medicine, and drug discovery. As AI becomes more deeply embedded in clinical research, companies have greater scope to improve trial design, identify treatment-responsive patient groups, and accelerate development of new therapies.

AI Expertise, Trust, and Reliable Clinical Data Remain Key Challenges

A major challenge for the AI in Clinical Trials Market is ensuring that AI-generated insights are supported by accurate, high-quality clinical data and can be used responsibly in regulated research environments. Organizations also need the right technical expertise to apply AI across trial phases and therapeutic areas. As AI adoption expands, maintaining data integrity, regulatory compliance, patient privacy, and confidence in AI-supported decision-making will remain central to long-term market development.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/222597/

Global AI in Clinical Trials Market Segmentation

The Global AI in Clinical Trials Market is segmented by Trial Phase, Technology, Application, End-Users, and Region. The market covers AI adoption across Phase I, Phase II, and Phase III clinical trials, with technologies such as machine learning, natural language processing, and deep learning supporting patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine. Pharmaceutical companies, research institutes, CROs, hospitals, and other end-users are increasingly integrating AI into clinical research workflows.

North America Leads the AI in Clinical Trials Market as Asia Pacific Gains Ground

North America leads the Global AI in Clinical Trials Market, supported by advanced healthcare infrastructure, a well-established pharmaceutical industry, strong investment in AI research, and growing collaboration between drug developers and technology companies. The United States remains the key market as AI is increasingly used for patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

Europe is also seeing steady adoption of AI in clinical research, particularly across the UK, Germany, and France. Strong pharmaceutical capabilities, established regulatory systems, government support for healthcare AI, and cross-border research partnerships are helping expand the use of machine learning and digital technologies in clinical trials.

Asia Pacific is emerging as an important market, led by China, India, and Japan. Large patient populations, expanding pharmaceutical sectors, and growing interest in more efficient and affordable clinical research are encouraging wider adoption of AI. Japan's advanced technology ecosystem is also creating opportunities for AI-driven healthcare and clinical trial applications.

South America and the Middle East & Africa remain developing markets for AI in Clinical Trials. Expanding pharmaceutical activity, improving healthcare infrastructure, evolving regulatory frameworks, and partnerships with international research and pharmaceutical organizations are supporting gradual adoption across these regions.

Leading Companies Expand the AI in Clinical Trials Market

Euretos, Biosymetrics, Unlearn.AI, Exscientia, AiCure, Antidote Technologies, Deep 6 AI, Innoplexus, IQVIA, Medidata, Mendel.ai, Phesi, Saama Technologies, Signant Health, Trials.ai, and other participants are active across the AI in Clinical Trials Market. These companies are developing solutions for patient recruitment, clinical data analysis, trial optimization, safety monitoring, and AI-supported drug development.

Global AI in Clinical Trials Market Competitive Landscape

Competition in the Global AI in Clinical Trials Market is becoming more technology-driven as companies focus on machine learning, deep learning, natural language processing, AI-powered patient recruitment, predictive analytics, and personalized medicine.

Concurrent DARPA awards provide non-dilutive funding to accelerate MagLev Aero's path to TRL-6 flight readiness, de-risking dual-use commercialization and advancing U.S.-manufactured propulsion for American "Drone Dominance" initiatives.

BOSTON, Sept. 25, 2026 /PRNewswire/ -- Propulsion has always been at the core of aircraft performance. As defense drones undergo a rapid performance escalation on the modern battlefield, there remains a critical, unmet need for advanced propulsion systems capable of establishing true drone air dominance. Addressing this challenge, MagLev Aero, a pioneer in advanced aerospace propulsion technology, today announced it has been selected by the Defense Advanced Research Projects Agency (DARPA) for concurrent awards under the Minimum Viable Product (MVP) and Embedded Entrepreneur Initiative (EEI) programs.

MagLev Aero has created a breakthrough in propulsion technology that provides more thrust for less power, fundamentally changing the physics of flight. This highly efficient architecture directly enables higher speeds, longer operational ranges, increased payload capacities, and a dramatically reduced noise signature—all the key domains required for drones that must evade detection and capture, counter-drones designed to catch and kill hostile threats, and cargo drones for contested logistics.

Supported by this non-dilutive government funding and an accelerating defense-market demand signal, MagLev Aero is advancing the industrialization of its next-generation propulsion platform. The platform is purpose-built to meet the surging demand for high-performance, U.S.-manufactured drone propulsion, aligning directly with White House "Drone Dominance" priorities, and the rapidly expanding commercial advanced air mobility (AAM) market. DARPA funding will support rapid advancement from prototype to flight-tested production, significantly reducing technical and integration risks for dual-use commercialization.

DARPA MVP - Accelerating Flight Readiness for Airframers

DARPA's MVP support helps technology developers quickly prototype, test, and adapt breakthroughs. MagLev Aero is funded to build and test a full-scale, flight-relevant propulsion demonstration platform, culminating in a Technology Readiness Level 6 (TRL-6) demonstration in a relevant operational environment. This effort significantly de-risks adoption for airframers and OEMs developing the next generation of autonomous drones and crewed aircraft by demonstrating:

DARPA EEI - Scaling U.S. Industrialization & Commercialization

Simultaneously, the DARPA EEI Program accelerates MagLev Aero's defense commercialization, go-to-market execution, and U.S. industrialization strategy. The award funds the embedding of an experienced business leader to help navigate federal acquisition frameworks and capture strategic transition opportunities.

"These dual DARPA contracts represent a major inflection point for MagLev Aero," said Ian Randall, Co-Founder and CEO of MagLev Aero. "We are not just proving out physics in a lab; we are helping build the propulsion industrial base for the next generation of American air power. By rapidly advancing our scalable, domestically manufactured propulsion platform to TRL-6, we are delivering a proven solution that meets the urgent national need for trusted, high-performance U.S. drone technologies."

About MagLev Aero

MagLev Aero is a Boston-based company developing the MagLev HyperDrive™ propulsion platform for the next generation of drones and advanced air vehicles. Backed by Breakthrough Energy Ventures and Material Impact, with 44 issued patents, its rim-driven ducted fan architecture leverages its patented MagLev HyperDrive™ technology. The company is devising a new engineering framework combining modern AI compute technology, multiphysics optimization, and human innovation to accelerate electrified propulsion design. The goal: unlock unprecedented levels of efficiency, range, payload, noise reduction, speed, and resiliency, directly enhancing operational capabilities for both defense and commercial aircraft applications.

Disclaimer: Any opinions, findings, conclusions, or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the Defense Advanced Research Projects Agency (DARPA).

Ian Randall

Co-Founder & CEO

linkedin.com/in/ian-randall-maglevaero

Media & Investor Contact:

Kerry Brackett

[email protected]

www.maglevaero.com

https://www.linkedin.com/company/maglev-aero/

SOURCE MagLev Aero

Share this article

WEBCO INDUSTRIES, INC. REPORTS FISCAL 2026 FOURTH QUARTER AND YEAR END RESULTS

SAND SPRINGS, Okla., Sept. 25, 2026 /PRNewswire/ -- Webco Industries, Inc. (OTC: WEBC) today reported results for our fourth fiscal quarter and year ended July 31, 2026.

For our fourth quarter of fiscal year 2026, we had net income of $5.0 million, or $7.35 per diluted share, while in our fourth quarter of fiscal year 2025, we had net income of $6.5 million, or $9.18 per diluted share. Net sales for the fourth quarter of fiscal 2026 were $189.7 million, a 19.9 percent increase from the $158.2 million in sales in the fourth quarter of fiscal year 2025.

For fiscal year 2026, we generated net income of $18.3 million, or $26.50 per diluted share, compared to a net income of $9.3 million, or $12.30 per diluted share, in fiscal year 2025. Net sales for the current fiscal year totaled $670.9 million, a 14.8 percent increase from the $584.7 million in sales for last year.

In the fourth quarter of fiscal year 2026, we had income from operations of $7.7 million after depreciation of $5.1 million. The fourth fiscal quarter of the prior year generated income from operations of $9.0 million after depreciation of $4.8 million. Gross profit for the fourth quarter of fiscal 2026 was $27.7 million, or 14.6 percent of net sales, compared to $22.0 million, or 13.9 percent of net sales, for the fourth quarter of fiscal year 2025.

Our income from operations for fiscal year 2026 was $28.0 million, after depreciation expense of $20.0 million. Income from operations in fiscal year 2025 was $16.6 million, after depreciation expense of $19.0 million. Gross profit for fiscal 2026 was $94.0 million, or 14.0 percent of net sales, compared to $66.8 million, or 11.4 percent of net sales for fiscal year 2025.

Selling, general and administrative expenses were $20.0 million in the fourth quarter of fiscal 2026 and $12.9 million in the fourth quarter of fiscal 2025. SG&A expenses were $66.0 million in fiscal year 2026 and $50.2 million for fiscal year 2025. SG&A expenses reflect increases in costs related to higher profitability, such as company-wide incentive compensation and variable pay programs, plus inflation we have experienced in wages and other expenses.

Interest expense was $1.5 million in the fourth quarter of fiscal year 2026 and $1.4 million in the same quarter of fiscal year 2025. Interest expense was $5.9 million and $5.3 million in the current and prior fiscal years, respectively. Interest expense increased due to higher average debt balances than in the prior fiscal periods.

Capital expenditures incurred amounted to $1.8 million in the fourth quarter of fiscal year 2026 and $15.4 million for fiscal year 2026. Capital spending in fiscal year 2026 has been focused on plant equipment updates and improvements.

At July 31, 2026, we had $9.1 million in cash and short-term investments, in addition to $112.9 million of available borrowing under our $220 million senior revolving credit facility. Availability on the revolver, which had $89.3 million drawn at July 31, 2026, is subject to advance rates on eligible accounts receivable and inventories. In February 2026, we extended the maturity on our debt agreement to February 2031. Accounting rules require asset-based debt agreements like our revolver to be classified as a current liability, despite its fiscal year 2031 maturity.

Webco's stock repurchase program authorizes the purchase of our outstanding common stock in private or open market transactions. In March 2026, the Company's Board of Directors refreshed the repurchase program with a new limit of up to $6.0 million and extended the program's expiration until July 31, 2029. We purchased 11,900 shares of our stock during the fourth quarter of fiscal year 2026 and 33,800 shares in fiscal year 2026. At July 31, 2026, there was approximately $1.6 million of purchase authority left in the current stock repurchase program. The repurchase plan may be extended, suspended or discontinued at any time, without notice, at the Board's discretion.

Webco's mission is to continuously build on our strengths as we create a vibrant company for the ages. We leverage our core values of trust and teamwork, continuously building strength, agility and innovation. We focus on practices that support our brand such that we are 100% engaged every day to build a forever kind of company for our Trusted Teammates, customers, business partners, investors and community. We provide high-quality carbon steel, stainless steel and other metal specialty tubing products designed to industry and customer specifications. We have five tube production facilities in Oklahoma and Pennsylvania and eight value-added facilities in Oklahoma, Illinois, Michigan, Pennsylvania and Texas, serving customers globally. Our F. William Weber Leadership Campus is in Sand Springs, Oklahoma and houses our corporate offices and our Webco TechCenter™, providing a state-of-the-art laboratory and R & D facility to lead and develop technical solutions for the metal tubing industry.

Risk Factors and Forward-looking statements: Certain statements in this release, including, but not limited to, those preceded by or predicated upon the words "anticipates," "appears," "believes," "estimates," "expects," "forever," "hopes," "intends," "plans," "projects," "pursue," "should," "will," "wishes," or similar words may constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievements expressed or implied herein. Such risks, uncertainties and factors include the factors discussed above and, among others: general economic and business conditions, including any global economic downturn; government policy or low hydrocarbon prices that stifle domestic investment in energy; competition from foreign imports, including any impacts associated with dumping or the strength of the U.S. dollar; political or social environments that are unfriendly to industrial or energy-related businesses; changes in manufacturing technology; the banking environment, including availability of adequate financing; worldwide and domestic monetary policy; changes in tax rates and regulation; regulatory and permitting requirements, including, but not limited to, environmental, workforce, healthcare, safety and national security; availability and cost of adequate qualified and competent personnel; changes in import / export tariff or restrictions; volatility in raw material cost and availability for the Company, its customers and vendors; the cost and availability, including time for delivery, of parts and services necessary to maintain equipment essential to the Company's manufacturing activities; the cost and availability of manufacturing supplies, including process gases; volatility in oil, natural gas and power cost and availability; world-wide or national transition from hydrocarbon sources of energy that adversely impact demand for our products; problems associated with product development efforts; significant shifts in product demand away from internal combustion engine automobiles; appraised values of inventories that can impact available borrowing under the Company's credit facility; declaration of material adverse change by a lender; industry capacity; domestic competition; loss of, or reductions in, purchases by significant customers and customer work stoppages; work stoppages by critical suppliers; labor unrest; conditions, including acts of God, that require more costly transportation of raw materials; accidents, equipment failures and insured or uninsured casualties; third-party product liability claims; flood, tornado, winter storms and other natural disasters; customer or supplier bankruptcy; customer or supplier declarations of force majeure; customer or supplier breach of contract; insurance cost and availability; lack of insurance coverage for floods; the cost associated with providing healthcare benefits to employees; customer claims; supplier quality or delivery problems; technical and data processing capabilities; cyberattack on our information technology infrastructure; world, domestic or regional health crises; vaccine mandates or related governmental policy that would cause significant portions of our workforce, or that of our customers or vendors, to leave their current employment; global or regional wars and conflicts; our inability or unwillingness to comply with rules required to maintain the quotation of our shares on any market place; and our inability to repurchase the Company's stock. The Company assumes no obligation to publicly update any such forward-looking statements. No assurance is provided that current results are indicative of those that will be realized in the future.

TABLES FOLLOW

SOURCE Webco Industries, Inc.

Share this article

SOUTHLAKE, Texas, Sept. 25, 2026 /PRNewswire/ -- Sabre Corporation ("Sabre") (Nasdaq: SABR) today announced the early tender results of the previously announced cash tender offer (the "Tender Offer") by Sabre Financial Borrower, LLC ("Sabre Financial"), its indirect wholly-owned subsidiary, for any and all of Sabre Financial's securities set forth in the table below (the "Securities") and concurrent solicitation of consents (the "Consent Solicitation") to certain proposed amendments to the Securities and the Indenture (as defined below). The Tender Offer and Consent Solicitation will expire at 5:00 p.m., New York City time, on October 12, 2026 (unless extended or earlier terminated, the "Expiration Date").

The Tender Offer and Consent Solicitation are being made pursuant to the terms and conditions set forth in the offer to purchase and consent solicitation statement, dated September 14, 2026 (the "Offer to Purchase").

As of 5:00 p.m., New York City time, on September 25, 2026 (such date and time, the "Early Tender Deadline" and "Withdrawal Deadline," as applicable), according to information provided to D.F. King & Co., Inc., the tender and information agent for the Tender Offer and Consent Solicitation, the aggregate principal amount of Securities listed in the table below has been validly tendered and not validly withdrawn in the Tender Offer and Consent Solicitation. Withdrawal rights for the Securities expired at the Early Tender Deadline and, accordingly, any Securities that were validly tendered may no longer be withdrawn except where additional withdrawal rights are required by law.

The Tender Offer and Consent Solicitation remain subject to the satisfaction or waiver of the conditions described in the Offer to Purchase, including the financing for the Tender Offer and Consent Solicitation. Such conditions may be waived by Sabre Financial in its sole discretion, subject to applicable law. Any waiver of a condition by Sabre Financial will not constitute a waiver of any other condition. Subject to the satisfaction or waiver of such conditions and as described in the Offer to Purchase, Sabre Financial is expected to make payment on September 28, 2026 (such date and time, as it may be extended, the "Early Settlement Date") for the Securities and related consents that (i) were validly tendered and delivered, as applicable, and not validly withdrawn or revoked, as applicable, at or prior to the Early Tender Deadline and (ii) are accepted for purchase on the Early Settlement Date.

The consideration to be paid for the Securities accepted for purchase on the Early Settlement Date per $1,000 principal amount of Securities is the amount set forth in the table above under the heading "Total Consideration." The amounts set forth in the table above under "Total Consideration" include an early tender premium of $50 per $1,000 principal amount of Securities accepted for purchase (the "Early Tender Premium"). All Holders of Securities accepted for purchase will also receive accrued and unpaid interest from the most recent interest payment date preceding the Early Settlement Date to, but not including, the Early Settlement Date.

Any Holder who tenders Securities in the Tender Offer and Consent Solicitation will be deemed to automatically have provided consents, and Securities may not be tendered without delivering consents. Based on the consents received as of the Early Tender Deadline, Sabre Financial has obtained the required consents to effect all of the proposed amendments (the "Proposed Amendments") as described in the Offer to Purchase. Consequently, as previously announced, Sabre Financial expects to execute a supplemental indenture (the "Supplemental Indenture") effecting the Proposed Amendments with respect to the indenture dated December 5, 2025 (the "Indenture"), entered into by and among Sabre Financial, the guarantors party thereto, and Wilmington Trust, National Association, as trustee and collateral agent, under which the Securities were issued, and the Securities on or about the Early Settlement Date. The Supplemental Indenture will become effective upon (a) its execution and delivery by each of the parties thereto, and (b) the settlement of the Tender Offer with respect to accepted Securities tendered prior to the Early Tender Deadline on the Early Settlement Date.

In addition, pursuant to the terms of the Indenture, because more than 90% of the aggregate principal amount of the Securities outstanding has been validly tendered in the Tender Offer, Sabre Financial intends, following its purchase of the tendered Securities, to deliver a notice of redemption to redeem all Securities that remain outstanding after giving effect to the purchase of the Securities on the Early Settlement Date. The redemption price for such Securities will be equal to the Total Consideration set forth in the table above, plus accrued and unpaid interest thereon to, but excluding, the redemption date. The redemption date is expected to be October 13, 2026. Notwithstanding the foregoing, there can be no assurance that any Securities will be redeemed. Nothing herein shall constitute a notice of redemption with respect to the Securities.

Sabre Financial reserves the right, subject to applicable law, in its sole discretion, to waive any of the conditions of the Tender Offer or the Consent Solicitation, in whole or in part, at any time and from time to time. It also reserves the right, subject to applicable law, in its sole discretion, (1) to terminate or withdraw the Tender Offer or the Consent Solicitation at any time; (2) to extend the Early Tender Deadline, the Withdrawal Deadline or the Expiration Date; or (3) otherwise to amend the Tender Offer or Consent Solicitation in any respect. It may extend the Early Tender Deadline without extending the Withdrawal Deadline.

Information Relating to the Tender Offer and Consent Solicitation

The complete terms and conditions of the Tender Offer and Consent Solicitation are set forth in the Offer to Purchase. BofA Securities is the Dealer Manager and Solicitation Agent for the Tender Offer and Consent Solicitation. Investors with questions regarding the Tender Offer and Consent Solicitation may contact BofA Securities, collect: (980) 388-3646, toll-free: (888) 292-0070, email: [email protected]. D.F. King & Co., Inc. is the tender and information agent for the Tender Offer and Consent Solicitation. Copies of the Offer to Purchase and any related offer documents may be obtained by contacting D.F. King & Co., Inc. by phone at (646) 455-1060 (New York) or (866) 356-7814 (toll-free) or by email at [email protected].

None of Sabre Financial, Sabre, their affiliates, their respective boards of directors and stockholders, the Dealer Manager and Solicitation Agent, the Tender Agent or Wilmington Trust, National Association, as trustee for the Securities, are making any recommendation as to whether Holders should tender any Securities or deliver any Consent in response to the Tender Offer and Consent Solicitation. Holders must make their own decision as to whether to tender any of their Securities and deliver their Consents, and, if so, the principal amount of Securities to tender and Consents to deliver.

This press release is for informational purposes only and is not an offer to buy or a solicitation of an offer to sell any of the Securities, and the Tender Offer and Consent Solicitation do not constitute offers to buy or the solicitation of offers to sell Securities in any jurisdiction or in any circumstances in which such offers are unlawful. The full details of the Tender Offer and Consent Solicitation, including complete instructions on how to tender Securities and deliver Consents, are included in the Offer to Purchase. Holders are strongly encouraged to read carefully the Offer to Purchase because it will contain important information.

Forward-Looking Statements

Certain statements herein are forward-looking statements about trends, future events, uncertainties and our plans and expectations of what may happen in the future. Any statements that are not historical or current facts are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as "expect," "guidance," "outlook," "trend," "pro forma," "on course," "on track," "target," "potential," "benefit," "goal," "believe," "plan," "confident," "anticipate," "indicate," "trend," "position," "optimistic," "will," "forecast," "continue," "strategy," "estimate," "project," "may," "should," "would," "intend," or the negative of these terms, where applicable, or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. More information about potential risks and uncertainties that could materially affect our business and results of operations is included in the "Risk Factors" and "Forward-Looking Statements" sections in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 18, 2026 and in our other filings with the SEC, as well as other risks and uncertainties specified in the "Certain Significant Considerations" section of the Offer to Purchase. We cannot guarantee future events, including financing of the Tender Offer and Consent Solicitation and successful completion of the Tender Offer and Consent Solicitation, outlook, guidance, results, actions, levels of activity, performance or achievements. Readers are cautioned not to place undue reliance on these forward-looking statements.

Goforth & Marti allegedly failed to accurately record employees' time during their shifts. Allegedly, this resulted in violations of various California Labor Codes.

**THIS IS AN ATTORNEY ADVERTISEMENT**

KERN, Calif., Sept. 25, 2026 /PRNewswire/ -- The Los Angeles employment law attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, filed a class action complaint alleging that Goforth & Marti violated the California Labor Code. The Goforth & Marti class action lawsuit, Case No. 26CUB03152, is currently pending in the Kern County Superior Court of the State of California. A copy of the Complaint can be read here.

According to the lawsuit filed, Goforth & Marti, allegedly (a) failed to pay minimum wages, (b) failed to pay overtime wages, (c) failed to provide legally required meal and rest periods, (d) failed to provide accurate itemized wage statements, (e) failed to reimburse for required expenses, (f) failed to pay sick wages, and (g) failed to provide wages when due, all in violation of the applicable Labor Code sections listed in California Labor Code Sections 201-203, 226, 226.7, 233, 246, 510, 512, 1194, 1197, 1197.1, 2802, and the applicable Wage Order(s), and thereby gives rise to civil penalties as a result of such alleged conduct.

The lawsuit further alleges that Defendant failed to provide all the legally required off-duty meal and rest breaks and failed to compensate Plaintiffs for missed meal and rest breaks. These employees, from time to time, were denied their first rest periods of at least ten (10) minutes for some shifts worked of at least two (2) to four (4) hours, a first and second rest period of at least ten (10) minutes for some shifts worked of between six (6) and eight (8) hours, and a first, second and third rest period of at least ten (10) minutes for some shifts worked of ten (10) hours or more, from time to time. Defendant allegedly paid Plaintiffs less than they would have been paid had they been paid for their actual recorded time rather than "rounded" time. Allegedly, Defendant violated Cal. Lab. Code §§ 1194, 1197, and 1197.1 .

For more information about the class action lawsuit against Goforth & Marti, call (800) 568-8020 to speak to an experienced California employment attorney today.

Blumenthal Nordrehaug Bhowmik De Blouw LLP is an employment law firm with offices located in San Diego, San Francisco, Sacramento, Los Angeles, Riverside and Chicago that dedicates its practice to helping employees, investors and consumers fight back against unfair business practices, including violations of the California Labor Code and Fair Labor Standards Act. If you need help in collecting unpaid overtime wages, unpaid commissions, being wrongfully terminated from work, and other employment law claims, contact one of their attorneys today.

**THIS IS AN ATTORNEY ADVERTISEMENT**

Media Contact

Nicholas De Blouw

Blumenthal Nordrehaug Bhowmik De Blouw LLP

(800) 568-8020

[email protected]

https://www.bamlawca.com/ 

SOURCE Blumenthal Nordrehaug Bhowmik De Blouw LLP

Share this article

MEMPHIS, Tenn., Sep 25, 2026 /PRNewswire/ -- International Paper (NYSE: IP; LSE: IPC) Chief Executive Officer Andy Silvernail will speak at the Baird 2026 Global Industrial Conference on November 11, 2026. The Fireside Chat and Q&A session is scheduled to begin at 8:30 a.m. ET (7:30 a.m. CT).

All interested parties are invited to listen to the webcast via the company's website by clicking on the Investors tab and going to the Events & Presentations page at https://www.internationalpaper.com/investors/events-presentations. A replay of the webcast will be available on the website approximately three hours after the presentation.

About International Paper (NYSE: IP; LSE: IPC)

International Paper creates sustainable packaging solutions that enable our customers, teammates and shareowners to thrive in an ever-changing world. We are a leader in corrugated packaging, partnering with customers across industries to protect what matters most, strengthen supply chains and create lasting value. Learn more at internationalpaper.com.

SOURCE International Paper

Share this article

JACKSON, Miss., Sept. 25, 2026 /PRNewswire/ -- EastGroup Properties, Inc. (NYSE: EGP) (the "Company", "we", "our", "us", or "EastGroup") announced today that it will hold its Third Quarter 2026 Earnings Conference Call and Webcast on Thursday, October 22, 2026, at 10:00 a.m. Eastern Time. On the call, senior management will discuss the Company's third quarter results, current operations, and earnings outlook for 2026.

EastGroup plans to release financial results for the quarter after the market closes on Wednesday, October 21, 2026. The earnings release and supplemental information package will be posted on the Company's website, www.eastgroup.net, at that time.

A live broadcast of the conference call is available by dialing 1-800-836-8184 (conference ID EastGroup) or by webcast through a link on the Company's website at www.eastgroup.net. If you are unable to listen to the live conference call, a telephone and webcast replay will be available on Thursday, October 22, 2026. The telephone replay will be available through Thursday, October 29, 2026, and can be accessed by dialing 1-888-660-6345 (access code 87577#). The webcast replay can be accessed through a link on the Company's website at www.eastgroup.net.

About EastGroup Properties, Inc.

EastGroup, a member of the S&P Mid-Cap 400 and Russell 2000 Indexes, is a self-administered equity real estate investment trust focused on the development, acquisition and operation of industrial properties in high-growth markets throughout the United States with an emphasis in the states of Texas, Florida, California, Arizona and North Carolina. The Company's goal is to maximize shareholder value by being a leading provider in its markets of functional, flexible and quality business distribution space for location sensitive customers (primarily in the 20,000 to 100,000 square foot range). The Company's strategy for growth is based on ownership of premier distribution facilities generally clustered near major transportation features in supply-constrained submarkets. The Company's portfolio, including development projects and value-add acquisitions in lease-up and under construction, currently includes approximately 66.8 million square feet.

EastGroup Properties, Inc. press releases are available at www.eastgroup.net.

Contact: [email protected]

SOURCE EastGroup Properties

Share this article

PUNE, India, Sept. 25, 2026 /PRNewswire/ -- The Global Knee Replacement Market was valued at USD 12.17 Billion in 2025 and is projected to expand at a 4.32% CAGR from 2026 to 2034, reaching USD 17.81 Billion by 2034, according to a new analysis by Maximize Market Research.

Global Knee Replacement Market

The Global Knee Replacement Market Report 2026 provides a comprehensive analysis of knee replacement market trends, orthopedic implant adoption, knee arthroplasty procedures, robotic-assisted knee replacement, AI-enabled surgical planning, implant technologies, minimally invasive orthopedic surgery, outpatient arthroplasty, cementless implants, patient-specific implants, smart implants, digital orthopedics, healthcare infrastructure, reimbursement trends, competitive landscape, technology advancements, and market forecasts through 2034. The market covers knee replacement solutions across Total Knee Replacement, Partial Knee Replacement, Kneecap Replacement, and Complex Knee Replacement, with implant technologies including Fixed Bearing, Mobile Bearing, and Others, supporting the treatment of severe osteoarthritis, rheumatoid arthritis, degenerative joint disorders, chronic knee pain, mobility impairment, and complex knee conditions.

The rising prevalence of knee osteoarthritis, aging population, increasing obesity rates, growing demand for mobility-restoring treatments, and rising knee replacement procedure volumes are supporting the expansion of the global knee replacement market. Increasing adoption of robotic-assisted knee replacement, AI-powered surgical planning, computer-assisted navigation, patient-specific instrumentation, advanced orthopedic implants, minimally invasive knee surgery, and enhanced recovery protocols is transforming modern orthopedic care. Growing healthcare expenditure, improved access to specialized orthopedic services, favorable reimbursement policies, and increasing awareness of advanced knee replacement procedures are further creating opportunities for orthopedic device manufacturers and healthcare providers.

Advancements in robotic-assisted surgery, cementless knee implants, porous implant coatings, 3D-printed orthopedic implants, smart implants, digital rehabilitation, remote patient monitoring, and personalized orthopedic care are reshaping the knee replacement landscape. Increasing investments by orthopedic companies in robotic surgery platforms, advanced biomaterials, implant design, AI-enabled surgical technologies, outpatient arthroplasty, and digital orthopedic solutions are creating new opportunities across hospitals, orthopedic centers, and ambulatory surgery settings. Product launches, strategic acquisitions, robotic technology expansion, surgeon training programs, implant innovation, and geographic expansion are expected to strengthen the global knee replacement market through 2034.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/57801/

Global Knee Replacement Market gains momentum as rising osteoarthritis prevalence, population aging, increasing demand for mobility-restoring treatments, rapid adoption of robotic-assisted knee replacement, advancements in cementless and patient-specific implants, AI-enabled surgical planning, minimally invasive procedures, and smart orthopedic technologies accelerate innovation in joint replacement care: Maximize Market Research unveils key market insights.

Global Knee Replacement Market Size & Forecast

Global Knee Replacement Market Trends & Insights

- North America leads the Global Knee Replacement Market, supported by advanced healthcare infrastructure, high knee replacement procedure volumes, favorable reimbursement policies, strong presence of orthopedic device manufacturers, and widespread adoption of robotic-assisted knee replacement, AI-enabled surgical planning, computer-assisted navigation, advanced orthopedic implants, and outpatient arthroplasty.

- Asia-Pacific represents a high-growth region, driven by rapid population aging, rising prevalence of knee osteoarthritis, increasing healthcare expenditure, improving orthopedic healthcare infrastructure, growing awareness of knee replacement surgery, medical tourism, and increasing adoption of robotic surgery, minimally invasive knee replacement, advanced knee implants, and digital orthopedic technologies across China, India, Japan, South Korea, Australia, and other emerging markets.

- Robotic-assisted knee replacement is gaining rapid adoption, supported by the increasing use of AI-powered surgical planning, robotic navigation, patient-specific instrumentation, real-time surgical guidance, and computer-assisted orthopedic surgery. These technologies are helping healthcare providers improve implant positioning, surgical precision, joint alignment, procedural efficiency, and postoperative recovery while supporting the adoption of advanced total and partial knee replacement procedures.

- Cementless and advanced knee implants are gaining traction, driven by demand for improved biological fixation, implant longevity, reduced wear, and better long-term clinical outcomes. Advances in porous implant coatings, 3D-printed orthopedic implants, advanced biomaterials, fixed-bearing implants, mobile-bearing implants, and patient-specific implant designs are supporting innovation across total knee arthroplasty and complex knee replacement procedures.

- Outpatient knee replacement and minimally invasive orthopedic surgery are expanding, supported by enhanced recovery after surgery (ERAS) protocols, improved anesthesia, shorter hospital stays, digital rehabilitation, ambulatory surgery centers (ASCs), and remote patient monitoring. The shift toward outpatient arthroplasty, minimally invasive knee surgery, faster recovery, personalized rehabilitation, and value-based orthopedic care is creating new opportunities for healthcare providers and orthopedic device manufacturers.

- Smart implants and digital orthopedics are shaping the future of knee replacement, with increasing research and investment in connected orthopedic implants, wearable rehabilitation devices, AI-enabled postoperative analytics, remote patient monitoring, digital rehabilitation platforms, and personalized orthopedic treatment. These technologies are supporting continuous recovery monitoring, early identification of postoperative complications, and more personalized patient care.

Rising Incidence of Knee Osteoarthritis and Growing Surgical Demand Drive Market Growth

The increasing prevalence of knee osteoarthritis, rheumatoid arthritis, obesity, age-related joint degeneration, chronic knee pain, and mobility impairment is driving demand for knee replacement procedures worldwide. The growing aging population and rising number of patients seeking long-term pain relief and improved mobility are increasing the volume of total knee arthroplasty, partial knee replacement, and revision knee replacement procedures. Growing awareness of advanced orthopedic treatments and improved access to specialized healthcare are further supporting market expansion.

High Procedure Costs and Limited Access to Specialized Orthopedic Care Restrain Market Growth

The high cost of knee replacement surgery, advanced orthopedic implants, robotic-assisted surgical systems, AI-enabled surgical technologies, and postoperative rehabilitation can restrict market penetration, particularly in cost-sensitive and developing healthcare markets. Limited reimbursement coverage, shortages of specialized orthopedic surgeons, unequal access to advanced hospitals, and the high investment required for robotic surgery infrastructure can also create challenges for the adoption of premium knee replacement technologies.

Advancements in Robotic-Assisted Surgery and Advanced Implants Create Opportunities

Rapid advancements in robotic-assisted knee replacement, AI-powered surgical planning, computer-assisted navigation, patient-specific instrumentation, cementless knee implants, 3D-printed orthopedic implants, smart implants, and advanced biomaterials are creating new opportunities across the knee replacement market. These technologies are supporting greater surgical precision, improved implant positioning, enhanced joint alignment, faster recovery, and improved long-term patient outcomes. Increasing investment by orthopedic device manufacturers in next-generation knee implants, robotic surgery platforms, digital orthopedics, and personalized orthopedic care is further expanding market opportunities.

Complex Surgical Procedures and Unequal Healthcare Infrastructure Create Challenges

The adoption of advanced knee replacement technologies can be affected by the complexity of surgical procedures, postoperative rehabilitation requirements, and variations in healthcare infrastructure across regions. Limited availability of robotic-assisted surgery systems, specialized orthopedic centers, trained surgeons, advanced diagnostic imaging, digital rehabilitation platforms, and modern implant technologies can restrict adoption in emerging markets. In addition, postoperative complications, implant wear, revision surgery, and long-term rehabilitation requirements can increase the overall treatment burden for patients and healthcare providers.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/57801/

Global Knee Replacement Market Segmentation

The Global Knee Replacement Market is segmented by Product, Implant, End-User, and Region.

MIAMI, Sept. 25, 2026 /PRNewswire/ -- For the 10th year, global law firm Greenberg Traurig, P.A. has been recognized as a "Florida Regional Powerhouse" by Law360 for successfully representing clients in key transactions and matters that impact the region.

Founded in Miami in 1967, Greenberg Traurig now has more than 400 attorneys across six Florida offices. As the Am Law 20 firm with the largest attorney presence in the state, the firm continues to advise clients on many of Florida's most significant litigation, real estate, corporate, and public finance matters.

"From securing landmark litigation victories to advising on transformative transactions and infrastructure projects, our Florida attorneys remain committed to serving clients on the state's most complex and impactful matters," Greenberg Traurig Senior Chairman Matthew B. Gorson said. "Being recognized as a Law360 Florida Powerhouse for the 10th year reflects our deep roots in Florida, our commitment to the state's continued growth, and the dedication of our attorneys to helping shape the future of the communities where we live and work."

Over the last year, Greenberg Traurig's Florida Litigation Practice secured significant victories across the state, including representing nine affiliates of Swire Properties in a landmark construction defect lawsuit involving Brickell City Centre, resulting in one of the largest recoveries in a construction defect matter in Florida history. The team also won a landmark appellate victory for Lyft before Florida's Third District Court of Appeal and represented the Florida State University Board of Trustees in litigation involving the Atlantic Coast Conference's Grant of Rights and member exit provisions.

Greenberg Traurig attorneys played a key role in helping to bring Miami Freedom Park and the city's new Major League Soccer stadium to fruition through years of land use, environmental, zoning, entitlement, permitting, and remediation work for the transformational development project.

The firm's Florida Real Estate Practice advised clients on some of the year's most notable transactions, including representing Kayne Anderson Real Estate and Remedy Medical Properties in their $7.2 billion acquisition of 296 outpatient medical properties from Welltower. The team also guided Swire Properties through the $512 million sale of a majority stake in the retail and parking components of Miami's Brickell City Centre and advised Royal Caribbean on a $292 million port and land acquisition supporting the development of Perfect Day Mexico.

Greenberg Traurig's Corporate Practice represented The Baldwin Group in its more than $1 billion merger with CAC Group and advised Fresh Del Monte Produce Inc. in its $285 million acquisition of Del Monte Foods assets, reuniting the Del Monte brand under one owner for the first time in nearly four decades.

The Public Finance & Infrastructure team advised on more than 120 financings with an aggregate value of approximately $10.5 billion, including representing Brightline in connection with more than $1.9 billion in revenue bond remarketings and serving as bond counsel on multiple statewide financings for the Florida Department of Transportation totaling approximately $2.7 billion.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

Media Contact

Elaine Walker

[email protected]

T +1 305.579.0832

SOURCE Greenberg Traurig, LLP

Share this article

Diamond Certified utilizes research-grade methodology to stand apart from paid advertising and crowdsourced reviews.

PETALUMA, Calif., Sept. 25, 2026 /PRNewswire/ -- American Ratings Corporation, the creator of Diamond Certified Resource, the source for consumers who love quality local companies, has published a new article on diamondcertified.org titled, "Paid Advertising vs. Earned Certifications: The Diamond Certified Difference." The piece explains how Diamond Certified differs from advertising-funded review platforms by using verified customer surveys, rigorous qualification standards, credentials checks and ongoing performance monitoring.

All organizations that certify local companies rely on one or more funding sources: advertising, donations, company-paid subscriptions or consumer-paid subscriptions. They use these funds to create methodology, conduct operations, verify information, analyze results, deny or award certifications and monitor the performance of each certified company. Some spend even more on customer satisfaction surveys and collection of original research data.

Professional ethics matter most, starting with ratings methodology.

While all certifying organizations require funding, the highly ethical ones don't allow their funding sources to bias the results. In the case of 25-year-old American Ratings Corporation, creator of Diamond Certified Resource, high ethics and accuracy start with its methodology creation, which includes funding customer satisfaction surveys and collection of original research data. Any local company can apply for the certification and pay a small rating fee, whether they pass or fail. The Diamond Certified bar is set high, though. Only companies that achieve a customer satisfaction rating of 90 or higher on a 100-point scale for Highest in Quality and Helpful Expertise and pass all required credentials checks earn Diamond Certified. Companies that fall short of these high standards don't earn Diamond Certified, regardless of how much they'd be willing to pay.

Advertising funds crowdsourced review sites.

This isn't inherently a bad thing, but it does mean these sites must generate mass traffic and monetize company owners' interest to fund their business. To gain a high volume of reviews and a large number of companies, they use review intake methods that allow non-customers to post reviews and company owners to seed and cherry-pick only satisfied customers for review solicitations. Unfortunately, they're plagued by fake and cherry-picked reviews, which has resulted in massive star score inflation. A recent study by SEO Bandwagon concludes that two-thirds of rated Google business profiles hold at least a 4.5 star rating, with plumbers and roofers scoring an average 4.9 stars. Since most local companies have a star rating score that used to be held only by the top rated, consumers are forced to wade through reviews and see if they can purge fake and misleading ones in their minds.

Diamond Certified Resource's professional ethics, ratings methodology and experienced team

Having started their customer satisfaction research in the early 1990s, the founders of Diamond Certified are pioneers in creating certifications for local companies based on customer satisfaction surveys. The Diamond Certified Research Team is also deeply experienced in ratings and research, with most managers having served on the team for more than two decades. Team members are committed to maintaining high ethical standards and producing highly accurate company ratings and research. Founder/CEO Greg Louie describes their core principle as simple but powerful. "No company is awarded Diamond Certified unless it truly earns it," he says. "Also, companies must maintain their Highest in Quality and Helpful Expertise status or we take it from them."

What is Diamond Certified?

Created by American Ratings Corporation in 2001, the Diamond Certified Research Team rates local companies (mostly contractors and service companies) on customer satisfaction, quality and Helpful Expertise®. To earn Diamond Certified, companies must apply and pay a small rating fee, pass or fail. Then the Diamond Certified Research Team puts the company through a rigorous 12-step rating process, which includes in-depth customer satisfaction surveys and credentials verification.

The rating fee does not influence the results. In fact, most companies can't qualify.

The Diamond Certified Research Team does not use any unverified online reviews. It conducts independent, research-grade ratings and research of only verified customers. Here's a simple summary of its rating process:

- A local company applies for Diamond Certified. The Diamond Certified Research Team gathers a customer list of all past customers during the previous year or a random sample of 400 customers for larger companies. Researchers conduct telephone and email surveys of these customers at random and verify that each respondent is an actual customer before proceeding. This process prevents surveying fake or cherry-picked customers.

- During these live telephone interviews, surveyed customers evaluate the company's work quality, whether the company provided Helpful Expertise and whether the client would use the company again. In addition to collecting customers' scores for the company, researchers record verbatim responses to open-ended questions.

- The Diamond Certified Research Team calculates an overall customer satisfaction rating on a 100-point scale for Highest in Quality and Helpful Expertise and verifies the company's credentials. Only companies that achieve a customer satisfaction rating of 90 or higher on a 100-point scale for Highest in Quality and Helpful Expertise and pass all required credentials checks earn Diamond Certified. The team then calculates a Star Equivalent Score for each verified customer rating by weighting a Quality score on a scale of 1 to 10, a YES/NO Loyalty (intent to return) score and a YES/NO Helpful Expertise score.

- The team produces a bound, printed report (25-30 pages) that includes verification of applicable state licenses and confirmation of required general liability and workers' compensation insurance coverage.

- Companies that meet all of Diamond Certified's high standards are awarded the prestigious Diamond Certified, and their complete ratings and research report is posted to their Diamond Certified Company Report at www.diamondcertified.org.

- The Diamond Certified Research Team then monitors each Diamond Certified company's performance and produces ongoing ratings and research. Each Diamond Certified Company Report is the most accurate and deeply researched report available anywhere on that company. It includes ratings, verbatim survey responses, researched articles, a capabilities table, charts, videos, photos, and expert profiles and advice.

"Companies that maintain their Diamond Certified status also agree to additional levels of oversight," says Director of Ratings David Pak. "For example, they must participate in ongoing verified customer surveys and research interviews, which are published on their Diamond Certified Company Report at diamondcertified.org."

"We also track voluntary customer feedback between survey periods," adds Greg Louie. "A company may face suspension or termination if that feedback reveals a concerning pattern of business practices, even if its overall survey score remains high."

Consumers who work with a Diamond Certified company also receive mediation support and are backed by the Diamond Certified Performance Guarantee for up to $1,000.

The Diamond Certified Difference

Diamond Certified gives consumers a researched basis for choosing a quality local company: verified customer surveys, rigorous qualification standards, credentials verification, in-depth company-specific research, and ongoing performance ratings and monitoring. Companies can't buy their way into Diamond Certified. They must earn it and keep earning it to retain it.

For consumers, that means greater confidence when choosing a high-quality local company. The ratings and research behind each Diamond Certified company are available for free at www.diamondcertified.org, so consumers can examine the ratings, read customers' verbatim responses, explore the in-depth research and make an informed choice.

It's easy to find top rated companies in the San Francisco Bay Area and Other Areas on Diamond Certified Resource.

Alameda County

Contra Costa County

El Dorado County

Fresno County

Los Angeles County

Marin County

Milwaukee County

Monterey County

Napa County

Orange County

Placer County

Sacramento County

San Benito County

San Francisco

San Joaquin County

San Mateo County

Santa Clara County

Santa Cruz County

Solano County

Sonoma County

Yolo County

Yuba County

About American Ratings Corporation

American Ratings Corporation (ARC), the creator of Diamond Certified Resource, the source for consumers who love quality local companies, rates local companies by surveying only their verified real customers to produce the country's most accurate ratings of local companies. It also creates deeply researched company reports and consumer guides that give consumers the best companies plus the best advice for choosing a local Auto, Home, Health or Personal service type of company.

Only companies rated Highest in Quality and Helpful Expertise® earn Diamond Certified and are backed by their Performance Guarantee. All their deeply researched reports and guides are available for free at diamondcertified.org. They also produce an annual, full-color, printed Diamond Certified Directory with 840,000 copies published in 9 geographic zones in the Greater San Francisco Bay Area. Each April, these are mailed for free to their 182,000 Diamond Certified Preferred Members and selected homeowners and companies.

SOURCE American Ratings Corporation

Share this article